MCID: CYT008
MIFTS: 61

Cytomegalovirus Infection

Categories: Blood diseases, Immune diseases

Aliases & Classifications for Cytomegalovirus Infection

MalaCards integrated aliases for Cytomegalovirus Infection:

Name: Cytomegalovirus Infection 55 17 3
Cytomegalovirus Infections 44 74

Classifications:



External Ids:

UMLS 74 C0010823

Summaries for Cytomegalovirus Infection

NINDS : 55 Cytomegalovirus (CMV) is a virus found throughout the world that infects between 50 to 80 percent of all adults in the United States by the age of 40.  CMV is in the same family of viruses that causes cold sores (herpes simplex virus), infectious mononucleosis (Epstein-Barr virus), and chickenpox/shingles (varicella zoster virus).    Most people who acquire CVM as children or adults display no signs of illness or have mild symptoms such as fever, fatigue, or tender lymph nodes.  People with a compromised immune system may have more severe forms of infection involving the nervous system. A hallmark of CMV infection is that the virus cycles through periods of dormancy and active infection during the life of the individual  Infected persons of any age periodically shed the virus in their body fluids, such as saliva, urine, blood, tears, semen, or breast milk.  CMV is most commonly transmitted when infected body fluids come in contact with the mucous membranes of an uninfected person, but the virus can also pass from mother to fetus during pregnancy.  

MalaCards based summary : Cytomegalovirus Infection, also known as cytomegalovirus infections, is related to congenital cytomegalovirus and colitis, and has symptoms including fever and pruritus. An important gene associated with Cytomegalovirus Infection is RAG1 (Recombination Activating 1), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Mycophenolic acid and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include kidney, t cells and liver, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

MedlinePlus : 44 Cytomegalovirus (CMV) is a virus found around the world. It is related to the viruses that cause chickenpox and infectious mononucleosis (mono). Between 50 percent and 80 percent of adults in the United States have had a CMV infection by age 40. Once CMV is in a person's body, it stays there for life. CMV is spread through close contact with body fluids. Most people with CMV don't get sick and don't know that they've been infected. But infection with the virus can be serious in babies and people with weak immune systems. If a woman gets CMV when she is pregnant, she can pass it on to her baby. Usually the babies do not have health problems. But some babies can develop lifelong disabilities. A blood test can tell whether a person has ever been infected with CMV. Most people with CMV don't need treatment. If you have a weakened immune system, your doctor may prescribe antiviral medicine. Good hygiene, including proper hand washing, may help prevent infections. Centers for Disease Control and Prevention

CDC : 3 Cytomegalovirus (pronounced sy-toe-MEG-a-low-vy-rus), or CMV, is a common virus that infects people of all ages. Over half of adults by age 40 have been infected with CMV. Once CMV is in a person’s body, it stays there for life and can reactivate. Most people infected with CMV show no signs or symptoms. However, CMV infection can cause serious health problems for people with weakened immune systems and for unborn babies (congenital CMV).

Related Diseases for Cytomegalovirus Infection

Diseases related to Cytomegalovirus Infection via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 633)
# Related Disease Score Top Affiliating Genes
1 congenital cytomegalovirus 33.5 CCL2 IL1B TNF
2 colitis 31.3 CXCL8 IL1B IL6 TNF
3 inflammatory bowel disease 31.1 CXCL8 IL1B IL6 TNF
4 ulcerative colitis 31.1 CXCL8 IL1B IL6 TNF
5 hematopoietic stem cell transplantation 30.9 HLA-A HLA-B HLA-E IL6 TNF
6 rubella 30.8 HLA-A HLA-B TNF
7 toxoplasmosis 30.8 IL1B IL6 TNF
8 common variable immunodeficiency 30.6 FAS IL6 RAG1 TNF
9 systemic lupus erythematosus 30.6 CCL2 CCL5 FAS IL1B IL6 TNF
10 leukomalacia 30.6 IL6 TNF
11 acquired immunodeficiency syndrome 30.5 B2M CCL3 HLA-B IL1B IL6 TNF
12 chlamydia 30.5 CXCL8 IL1B IL6 TNF
13 crohn's colitis 30.5 CXCL8 IL1B TNF
14 arteries, anomalies of 30.4 CCL2 IL1B IL6 TNF
15 kawasaki disease 30.4 CCL2 IL6 TNF
16 hemophagocytic lymphohistiocytosis 30.4 B2M CXCL8 FAS TNF
17 cerebral palsy 30.4 IL1B IL6 TNF
18 pertussis 30.4 IL1B IL6 TNF
19 perinatal necrotizing enterocolitis 30.4 CXCL8 IL1B IL6 TNF
20 myocarditis 30.4 HLA-B IL6 TNF
21 bronchiolitis 30.3 CCL3 CCL5 CXCL8 IL6 TNF
22 graft-versus-host disease 30.3 FAS HLA-A HLA-B IL1B IL6 TNF
23 acute respiratory distress syndrome 30.3 CXCL8 IL1B IL6 TNF
24 pneumonia 30.3 CCL2 CCL3 CCL5 CXCL8 IL1B IL6
25 arthritis 30.2 CCL2 CXCL8 IL1B IL6 TNF
26 encephalitis 30.2 CCL2 CCL5 IL1B IRF3
27 meningoencephalitis 30.2 B2M CCL5 IL6
28 cytomegalovirus retinitis 30.2 HLA-A HLA-B TNF
29 lyme disease 30.2 IL1B IL6 TNF
30 gastroenteritis 30.1 CXCL8 IL1B IL6 TNF
31 neuritis 30.1 CCL2 CCL5 IL1B TNF
32 human immunodeficiency virus infectious disease 30.1 B2M CCL3 CCL5 IL6 TNF
33 spondylitis 30.1 HLA-B IL6 TNF
34 pericarditis 30.1 IL1B IL6 TNF
35 cholangitis 30.1 HLA-B IL6 TNF
36 monocytic leukemia 30.1 CXCL8 IL1B IL6 TNF
37 duodenal ulcer 30.1 CXCL8 IL1B TNF
38 esophagitis 30.1 CXCL8 IL1B IL6
39 uveitis 30.1 CCL2 HLA-B TNF
40 central nervous system vasculitis 30.1 IL1B IL6 TNF
41 transverse myelitis 30.0 CXCL8 IL6 TNF
42 haemophilus influenzae 30.0 CXCL8 IL1B TNF
43 bronchiolitis obliterans 30.0 CXCL8 IL6 TNF
44 myeloma, multiple 30.0 B2M CCL3 CXCL8 IL6 TNF
45 endometritis 30.0 IL1B IL6 TNF
46 bacterial infectious disease 30.0 CCL2 CXCL8 IL1B IL6 TNF
47 human herpesvirus 8 30.0 HLA-A HLA-B IL6
48 adult-onset still's disease 30.0 IL1B IL6 TNF
49 monoclonal gammopathy of uncertain significance 29.9 B2M IL6 TNF
50 q fever 29.9 IL1B IL6 TNF

Comorbidity relations with Cytomegalovirus Infection via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Heart Disease

Graphical network of the top 20 diseases related to Cytomegalovirus Infection:



Diseases related to Cytomegalovirus Infection

Symptoms & Phenotypes for Cytomegalovirus Infection

UMLS symptoms related to Cytomegalovirus Infection:


fever, pruritus

GenomeRNAi Phenotypes related to Cytomegalovirus Infection according to GeneCards Suite gene sharing:

27 (show all 16)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-103 10.09 HLA-A HLA-B HLA-G
2 Increased shRNA abundance (Z-score > 2) GR00366-A-110 10.09 HLA-A HLA-B HLA-G
3 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.09 HLA-E
4 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.09 HLA-A HLA-B HLA-G
5 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.09 HLA-E
6 Increased shRNA abundance (Z-score > 2) GR00366-A-156 10.09 HLA-A HLA-B HLA-G
7 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.09 HLA-E
8 Increased shRNA abundance (Z-score > 2) GR00366-A-178 10.09 HLA-A HLA-B HLA-G
9 Increased shRNA abundance (Z-score > 2) GR00366-A-186 10.09 HLA-E
10 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.09 HLA-A HLA-B HLA-G
11 Increased shRNA abundance (Z-score > 2) GR00366-A-31 10.09 HLA-A HLA-B HLA-G HLA-E
12 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.09 HLA-A HLA-B HLA-G
13 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.09 HLA-A HLA-B HLA-G
14 Decreased viability with paclitaxel GR00179-A-1 9.8 MAPK3 MTOR SP1
15 Decreased viability with paclitaxel GR00179-A-2 9.8 MTOR
16 Decreased viability with paclitaxel GR00179-A-3 9.8 MAPK3 MTOR SP1

MGI Mouse Phenotypes related to Cytomegalovirus Infection:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.22 B2M CREB1 FAS HLA-G IL1B IL6
2 hematopoietic system MP:0005397 10.21 B2M CCL5 FAS HLA-G IL1B IL6
3 immune system MP:0005387 10.18 B2M CCL2 CCL5 FAS HLA-G IL1B
4 cardiovascular system MP:0005385 10.16 B2M CREB1 FAS IL1B IL6 MAPK3
5 integument MP:0010771 9.92 B2M FAS IL1B IL6 MAPK3 RAG1
6 liver/biliary system MP:0005370 9.8 B2M FAS IL6 MAPK3 RAG1 SP1
7 neoplasm MP:0002006 9.7 B2M FAS IL1B IL6 MAPK3 RAG1
8 respiratory system MP:0005388 9.56 CREB1 FAS IL6 MAPK3 MTOR RAG1
9 skeleton MP:0005390 9.28 CREB1 FAS IL1B IL6 MAPK3 MTOR

Drugs & Therapeutics for Cytomegalovirus Infection

Drugs for Cytomegalovirus Infection (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 272)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mycophenolic acid Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 24280-93-1 446541
2
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 53-03-2 5865
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 22916-47-8 4189
4
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
5
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 104987-11-3 445643 439492 6473866
6
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177 70789204
7
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
8
Acyclovir Approved Phase 4,Phase 3,Phase 2,Not Applicable 59277-89-3 2022
9
Ganciclovir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 82410-32-0 3454
10
Valganciclovir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 175865-60-8 64147
11
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 2921-57-5
12
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 83-43-2 6741
13
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 50-24-8 5755
14
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 302-25-0
15
Foscarnet Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 63585-09-1, 4428-95-9 3415
16
Cidofovir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 113852-37-2 60613
17
Basiliximab Approved, Investigational Phase 4,Not Applicable 152923-56-3, 179045-86-4
18
Pancrelipase Approved, Investigational Phase 4,Not Applicable 53608-75-6
19
Formaldehyde Approved, Vet_approved Phase 4 50-00-0 712
20
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
21
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
22
tannic acid Approved Phase 4 1401-55-4
23
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
24
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
25
Infliximab Approved Phase 4 170277-31-3
26
Probenecid Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 57-66-9 4911
27
Azathioprine Approved Phase 4 446-86-6 2265
28
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
29
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
30
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
31
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
32
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
33
Prednisolone hemisuccinate Experimental Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 2920-86-7
34
Phosphonoacetic Acid Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 4408-78-0 546
35 Triamcinolone hexacetonide Phase 4
36 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Not Applicable
37 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
38 Hormones Phase 4,Phase 3,Phase 2
39 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2
42 Hormone Antagonists Phase 4,Phase 3,Phase 2
43 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Not Applicable
45 Triamcinolone diacetate Phase 4
46 Antitubercular Agents Phase 4,Phase 3,Phase 2,Not Applicable
47 Antifungal Agents Phase 4,Phase 3,Phase 2,Not Applicable
48 triamcinolone acetonide Phase 4
49 Calcineurin Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 glucocorticoids Phase 4,Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 380)
# Name Status NCT ID Phase Drugs
1 Evaluation of Early Use of Everolimus (EVE) on Cytomegalovirus (CMV) Infection in Renal Transplant Recipients Unknown status NCT01927588 Phase 4 Everolimus+Tacrolimus+Prednisone;Mycophenolate+Tacrolimus+Prednisone
2 PTH - Preemptive Treatment for Herpesviridae Unknown status NCT02152358 Phase 4 Aciclovir;Ganciclovir;Placebo
3 Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection Completed NCT01509404 Phase 4 Valganciclovir;Valganciclovir
4 Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine A Completed NCT02328963 Phase 4 Everolimus;mycophenolic acid
5 Valganciclovir for Treatment of Cytomegalovirus Infection in Solid Organ Transplant Patients Completed NCT00730769 Phase 4 Single arm (ganciclovir and valganciclovir)
6 The Influence of Chronic CMV Infection on Influenza Vaccine Responses Completed NCT02134184 Phase 4
7 Prospective, Randomized Study for Predicting Human Cytomegalovirus (hCMV) Infection Based on Baseline hCMV Specific T-cell Response in Kidney Transplant Completed NCT02550639 Phase 4
8 Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant Patients Completed NCT02683291 Phase 4 sirolimus;tacrolimus;mycophenolate;Prednisone;Basiliximab;Thymoglobulin
9 Determining a Viral Load Threshold for Treating Cytomegalovirus (CMV) Completed NCT00947141 Phase 4 ganciclovir (start when CMV PCR >200copies / ml x2);Stop treatment when 2 levels CMV PCR <3,000 copies / ml
10 A Study of Oral Valcyte (Valganciclovir) in Pediatric Kidney Transplant Recipients Completed NCT01376804 Phase 4 valganciclovir [Valcyte]
11 Valganciclovir to Prevent Cytomegalovirus Infection in Kidney and Kidney/Pancreas Transplant Recipients Completed NCT00034385 Phase 4 Valganciclovir
12 CMV Antiviral Prevention Strategies in D+R-Liver Transplants ("CAPSIL") Completed NCT01552369 Phase 4 Valganciclovir
13 Influence of Persistent CMV-infection on Immune Senescence Completed NCT00461695 Phase 4
14 A Study on Spermatogenesis in Male Renal Transplant Recipients Receiving Valganciclovir (Valcyte®) Versus Untreated Matched Controls Completed NCT01663740 Phase 4 Valganciclovir
15 Prophylaxis With Ganciclovir Improves Graft Survival in Renal Allograft Recipients Completed NCT00373165 Phase 4 Ganciclovir
16 VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients Completed NCT00431353 Phase 4 Ganciclovir;valganciclovir [Valcyte]
17 Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate Completed NCT01354301 Phase 4 Thymoglobulin;Everolimus;Basiliximabe;mycophenolate sodium;Tacrolimus;Tacrolimus;Tacrolimus
18 Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant Completed NCT02084446 Phase 4 Everolimus;Very Low Tacrolimus;Low Tacrolimus;Steroids;Thymoglobulin;Sodium Mycophenolate
19 Valganciclovir to Reduce T Cell Activation in HIV Infection Completed NCT00264290 Phase 4 Valganciclovir;Placebo
20 Safety and Efficacy of Intravenous Magnesium Sulfate in Modulating Changes in Symptoms and Divalent Cation Levels Associated With Foscavir Therapy: A Phase IV Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Pilot Study Completed NCT00002146 Phase 4 Magnesium sulfate;Foscarnet sodium
21 Pharmacokinetics of Cidofovir During Continuous Venovenous Hemofiltration Completed NCT01866397 Phase 4
22 Individualization of Ganciclovir and Valganciclovir Doses Using Bayesian Prediction in Renal Transplant Patients. Completed NCT01446445 Phase 4 Ganciclovir/ Valganciclovir according to SPC;Ganciclovir/ Valganciclovir according to PK model
23 Study Comparing Cyclosporine With Infliximab in Steroid-refractory Severe Attacks of Ulcerative Colitis Completed NCT00542152 Phase 4 CYCLOSPORINE VS INFLIXIMAB
24 Safety Outcomes of Lower Immunosuppression Versus Traditional Immunosuppression in Heart Transplant Recipients Completed NCT00299221 Phase 4 Tacrolimus;combination therapy
25 Everolimus in de Novo Heart Transplant Recipients Completed NCT01017029 Phase 4 Everolimus;Mycophenolate mofetil + Everolimus
26 A Multicenter Study of Oral Versus Intravenous Hydration in AIDS Patients With CMV Retinitis Treated With Foscavir (Foscarnet Sodium) Completed NCT00002125 Phase 4 Foscarnet sodium
27 In Utero Treatment of Cytomegalovirus congénitale Infection With Valacyclovir Completed NCT01651585 Phase 4 Valacyclovir arrow
28 Efficacy and Safety of the Switch From Sirolimus to Everolimus in Stable Maintenance Renal Transplant Patients Receiving a Calcineurin Inhibitor Free Regimen Completed NCT00170820 Phase 4 Everolimus
29 Individually Adapted Immunosuppression in de Novo Renal Transplantation Based on Immune Function Monitoring: a Prospective Randomised Study Completed NCT00895206 Phase 4 individual adapted immunosuppression;golden standard therapy
30 Comparison of Two Drugs, Cidofovir and Ganciclovir, in Treating Patients With AIDS Who Have CMV Retinitis Completed NCT00000894 Phase 4 Cidofovir;Probenecid;Ganciclovir
31 Conversion to Sirolimus: Effects in Cytomegalovirus Infection Recurrence Recruiting NCT02671318 Phase 4 Drug conversion to sirolimus;Maintenance of the current regimen
32 CMV-CTL for the Treatment of CMV Infection After HSCT Recruiting NCT03004261 Phase 4 Foscarnet;Ganciclovir
33 Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney Transplantation Recruiting NCT03468478 Phase 4 Sirolimus;Everolimus;Mycophenolic acid
34 Topical 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis Recruiting NCT02943057 Phase 4 2% guttae ganciclovir
35 Efficacy and Safety of a Reduced Immunosuppression vs. Standard Triple Therapy in Senior Renal Transplant Recipients Not yet recruiting NCT02453867 Phase 4 Tacrolimus;mycophenolate;Steroids
36 In UTERO Treatment of Cytomegalovirus Congenital Infection With Valacyclovir Terminated NCT01037712 Phase 4 Valacyclovir (ZELITREX);Placebo
37 Ganciclovir Pharmacokinetics in Patients Undergoing Continuous Renal Replacement Therapy Terminated NCT00264368 Phase 4 intravenous (IV) ganciclovir
38 Correcting Anemia and Native Vitamin D Supplementation in Kidney Transplant Recipients Terminated NCT01817699 Phase 4
39 Prevention of Transplant Atherosclerosis With Everolimus and Anti-cytomegalovirus Therapy Unknown status NCT00966836 Phase 3 Pre-emptive strategy with valganciclovir plus everolimus;Prophylaxis with valganciclovir plus mycophenolate;Prophylaxis with valganciclovir plus everolimus;Pre-emptive mycophenolate
40 Congenital Cytomegalovirus: Efficacy of Antiviral Treatment Unknown status NCT02005822 Phase 3 Valganciclovir
41 Anti-T-Lymphocyte Globulin (ATG) in Renal Transplantation of Kidneys With a Non-Heart-Beating (NHB) Donor Unknown status NCT00733733 Phase 3 ATG Fresenius
42 Valganciclovir in Patients With CMV Retinitis and AIDS Who Cannot Take Drugs by Injection Unknown status NCT00017784 Phase 3 Valganciclovir
43 Efficacy Study of Human Cytomegalovirus (HCMV) Hyperimmune Globulin to Prevent Congenital HCMV Infection Completed NCT00881517 Phase 2, Phase 3 HCMV-specific hyperimmune globulin (Cytotect®);Isotonic solution of sodium chloride (placebo)
44 Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections Completed NCT00466817 Phase 3 Valganciclovir
45 Phase III Randomized, Controlled Study of Ganciclovir for Symptomatic Congenital Cytomegalovirus Infection Completed NCT00004278 Phase 3 ganciclovir
46 Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation Completed NCT00016068 Phase 3 ganciclovir;valganciclovir
47 Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients Completed NCT00411645 Phase 3 maribavir
48 Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) Disease in Liver Transplant Recipients Completed NCT00497796 Phase 3 maribavir;ganciclovir
49 Artesunate in Preemptive Treatment of Human Cytomegalovirus (CMV) in Stem Cell Transplant Recipients Completed NCT00284687 Phase 3 Artesunate
50 Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001) Completed NCT02137772 Phase 3 Letermovir;Placebo

Search NIH Clinical Center for Cytomegalovirus Infection

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Genetic Tests for Cytomegalovirus Infection

Anatomical Context for Cytomegalovirus Infection

MalaCards organs/tissues related to Cytomegalovirus Infection:

42
Kidney, T Cells, Liver, Bone, Lung, Bone Marrow, Testes

Publications for Cytomegalovirus Infection

Articles related to Cytomegalovirus Infection:

(show top 50) (show all 3842)
# Title Authors Year
1
Polymerase chain reaction for detection of mucosal cytomegalovirus infection in patients with acute ulcerative colitis. ( 30598596 )
2019
2
Magnetic resonance imaging of cerebellar cysts in a neonate with congenital cytomegalovirus infection. ( 30612159 )
2019
3
Prevalence of Congenital Cytomegalovirus Infection and Associated Risk of In-utero HIV Acquisition in a High HIV Prevalence Setting, South Africa. ( 30615106 )
2019
4
Prediction of the Outcome of Cochlear Implantation in the Patients with Congenital Cytomegalovirus Infection based on Magnetic Resonance Imaging Characteristics. ( 30682778 )
2019
5
Histopathological analysis of placentas with congenital cytomegalovirus infection. ( 30712668 )
2019
6
Association between neuroimaging findings and neurological sequelae in patients with congenital cytomegalovirus infection. ( 30857789 )
2019
7
Direct Saliva Real-time Polymerase Chain Reaction Assay Shows Low Birth Prevalence of Congenital Cytomegalovirus Infection in Urban Western India. ( 30882739 )
2019
8
Efficacy of Valganciclovir Treatment Depends on the Severity of Hearing Dysfunction in Symptomatic Infants with Congenital Cytomegalovirus Infection. ( 30893926 )
2019
9
Small Bowel Pyogenic Granuloma With Cytomegalovirus Infection in a Patient With Crohn's Disease (Report of a Case and Review of the Literature). ( 30587632 )
2019
10
Cytomegalovirus infection in day care centres: A systematic review and meta-analysis of prevalence of infection in children. ( 30306730 )
2019
11
Acute cytomegalovirus infection associated with pulmonary embolism treated successfully with rivaroxaban: case report. ( 30353451 )
2019
12
Restriction of Human Cytomegalovirus Infection by Galectin-9. ( 30487283 )
2019
13
Development of a predictive model using endoscopic features for gastric cytomegalovirus infection in renal transplant patients. ( 30507742 )
2019
14
Differential circRNA expression profiles in latent human cytomegalovirus infection and validation using clinical samples. ( 30576257 )
2019
15
Antigen-Specific TCR Signatures of Cytomegalovirus Infection. ( 30587531 )
2019
16
The clinical features and mortality risk factors of cytomegalovirus infection in patients with systemic lupus erythematosus. ( 30598425 )
2019
17
Antenatal Cytomegalovirus Infection Screening Results of 32,188 Patients in a Tertiary Referral Center: A Retrospective Cohort Study. ( 30600762 )
2019
18
Cytomegalovirus infection is not a major cause of corneal graft failure in the United Kingdom. ( 30622288 )
2019
19
Severe systemic cytomegalovirus infection in an immunocompetent patient outside the intensive care unit: a case report. ( 30626344 )
2019
20
Specific T-cell receptor gene transfer enhances immune response: A potential therapeutic strategy for the control of human cytomegalovirus infection in immunocompromised patients. ( 30626494 )
2019
21
Case report on early treatment with valaciclovir after maternal primary cytomegalovirus infection. ( 30634004 )
2019
22
Cytomegalovirus infection is associated with AML relapse after allo-HSCT: a meta-analysis of observational studies. ( 30666434 )
2019
23
Cytomegalovirus infection in Systemic Lupus Erythematosus: report of four cases challenging the management of the disease, and literature review. ( 30674220 )
2019
24
Factors associated with cytomegalovirus infection in children undergoing allogeneic hematopoietic stem-cell transplantation. ( 30681583 )
2019
25
Monitoring of cytomegalovirus infection in non-transplant pediatric acute lymphoblastic leukemia patients during chemotherapy. ( 30681620 )
2019
26
Killer Immunoglobulin-Like Receptor 2DS2 (KIR2DS2), KIR2DL2-HLA-C1, and KIR2DL3 as Genetic Markers for Stratifying the Risk of Cytomegalovirus Infection in Kidney Transplant Recipients. ( 30696053 )
2019
27
Characterization of Baboon Cytomegalovirus Infection in Healthy Adult Baboons (Papio anubis). ( 30704552 )
2019
28
Pulse corticosteroids in treatment of rheumatic disease concomitant with cytomegalovirus infection. ( 30740904 )
2019
29
Volumetric MRI Study of the Brain in Fetuses with Intrauterine Cytomegalovirus Infection and Its Correlation to Neurodevelopmental Outcome. ( 30760462 )
2019
30
The IκB kinases restrict human cytomegalovirus infection. ( 30760575 )
2019
31
Cytokine-Mediated Induction and Regulation of Tissue Damage During Cytomegalovirus Infection. ( 30761144 )
2019
32
A Prospective Multi-Center Observational Study of Cell-Mediated Immunity as a Predictor for Cytomegalovirus Infection in Kidney Transplant Recipients. ( 30768834 )
2019
33
Middle cerebral artery peak systolic velocity in perinatal cytomegalovirus infection. ( 30786033 )
2019
34
The Association of 25-Hydroxyvitamin D Levels with Late Cytomegalovirus Infection in Kidney Transplant Recipients: the Wisconsin Allograft Recipient Database (WisARD). ( 30801528 )
2019
35
Splenic rupture in cytomegalovirus infection. ( 30802994 )
2019
36
Cytomegalovirus infection with pulmonary embolism, splenic vein thrombosis and monoclonal gammopathy of undetermined significance: a case and systematic review. ( 30837233 )
2019
37
Association of Early-Life Stress With Cytomegalovirus Infection in Adults With Major Depressive Disorder. ( 30840037 )
2019
38
Mixed versus Full Donor Engraftment Early after Hematopoietic Cell Transplant: Impact on Incidence and Control of Cytomegalovirus Infection. ( 30864271 )
2019
39
Interferon-Independent Upregulation of Interferon-Stimulated Genes during Human Cytomegalovirus Infection is Dependent on IRF3 Expression. ( 30871003 )
2019
40
Evidence based on a meta-analysis of human cytomegalovirus infection in glioma. ( 30888562 )
2019
41
Late Cytomegalovirus Infection in Kidney Transplant Recipients after a Six-Month Prevention Protocol. ( 30891165 )
2019
42
Risk of Opportunistic Infection in Kidney Transplant Recipients with Cytomegalovirus Infection and Associated Outcomes. ( 30891915 )
2019
43
Cytomegalovirus Infection among Infants in Neonatal Intensive Care Units, California, 2005 to 2016. ( 30895580 )
2019
44
Chronic alcohol consumption exacerbates murine cytomegalovirus infection via impairing nonspecific and specific NK activation in mice. ( 30911737 )
2019
45
Reactivation of Latent Cytomegalovirus Infection after Major Surgery: Risk Factors and Outcomes. ( 30912706 )
2019
46
Prevention and treatment of fetal cytomegalovirus infection with cytomegalovirus hyperimmune globulin: a multicenter study in Madrid. ( 28978246 )
2019
47
Histological Analysis of Term Placentas from Hyperimmune Globulin-Treated and Untreated Mothers with Primary Cytomegalovirus Infection. ( 29684915 )
2019
48
Functional and clinical consequences of changes to natural killer cell phenotypes driven by chronic cytomegalovirus infections. ( 30636352 )
2019
49
Cytomegalovirus infection in the first year after pediatric kidney transplantation. ( 29887270 )
2018
50
Cytomegalovirus infection and steroid-refractory inflammatory bowel disease: possible relationship from an updated meta-analysis. ( 29392650 )
2018

Variations for Cytomegalovirus Infection

Expression for Cytomegalovirus Infection

Search GEO for disease gene expression data for Cytomegalovirus Infection.

Pathways for Cytomegalovirus Infection

Pathways related to Cytomegalovirus Infection according to GeneCards Suite gene sharing:

(show top 50) (show all 110)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.01 B2M CCL2 CCL3 CCL5 CREB1 CXCL8
2
Show member pathways
13.96 CCL2 CCL3 CCL5 CREB1 CXCL8 FAS
3
Show member pathways
13.79 CCL2 CCL3 CCL5 CREB1 CXCL8 FAS
4
Show member pathways
13.67 CREB1 CXCL8 FAS IL1B IL6 MAPK3
5
Show member pathways
13.65 CCL2 CCL3 CCL5 CREB1 CXCL8 IL1B
6
Show member pathways
13.55 B2M CREB1 HLA-A HLA-B HLA-E HLA-G
7
Show member pathways
13.53 CCL2 CCL3 CCL5 CREB1 CXCL8 FAS
8
Show member pathways
13.42 CCL2 CCL3 CCL5 CXCL8 FAS IL1B
9
Show member pathways
13.28 CCL2 CCL3 CCL5 CXCL8 FAS IL1B
10
Show member pathways
13.14 B2M CCL2 CCL3 CCL5 CXCL8 HLA-A
11
Show member pathways
13.07 CREB1 FAS HLA-A HLA-B HLA-E HLA-G
12
Show member pathways
13.06 CCL2 CCL5 FAS IL6 MAPK3 MTOR
13
Show member pathways
12.99 CCL2 CCL3 CCL5 CXCL8 FAS MAPK3
14 12.95 CXCL8 FAS IL6 MAPK3 MTOR SP1
15
Show member pathways
12.9 CCL5 CXCL8 IL1B IL6 IRF3 TMEM173
16
Show member pathways
12.86 CREB1 IL6 MAPK3 MTOR TNF
17
Show member pathways
12.8 CREB1 FAS IL1B MAPK3 SP1 TNF
18
Show member pathways
12.77 B2M CREB1 CXCL8 FAS HLA-A HLA-B
19
Show member pathways
12.74 CREB1 FAS IL1B IRF3 MAPK3 TNF
20
Show member pathways
12.73 B2M CCL2 CCL3 CCL5 CREB1 CXCL8
21
Show member pathways
12.7 IL1B IL6 MAPK3 MTOR TNF
22
Show member pathways
12.69 CCL2 IL1B IL6 MAPK3 TNF
23
Show member pathways
12.69 B2M HLA-A HLA-B HLA-E HLA-G IRF3
24 12.69 B2M CCL2 CCL5 FAS IL1B IRF3
25
Show member pathways
12.67 FAS HLA-A HLA-B HLA-E HLA-G MAPK3
26
Show member pathways
12.6 CREB1 IL1B MAPK3 MTOR SP1
27
Show member pathways
12.59 B2M HLA-A HLA-B HLA-E HLA-G
28
Show member pathways
12.58 CREB1 FAS IL1B IL6 MAPK3 TNF
29 12.51 CREB1 HLA-A HLA-B HLA-E HLA-G IL6
30
Show member pathways
12.48 CXCL8 MAPK3 MTOR SP1
31
Show member pathways
12.48 CCL2 CXCL8 IL1B IL6 MAPK3 SP1
32
Show member pathways
12.47 CCL2 CREB1 MAPK3 SP1
33 12.47 HLA-A HLA-B HLA-E HLA-G
34
Show member pathways
12.46 CREB1 CXCL8 IL1B IL6 IRF3 MAPK3
35
Show member pathways
12.45 CCL2 CCL5 IL1B IL6 TNF
36 12.44 CREB1 HLA-A HLA-B HLA-E HLA-G IRF3
37
Show member pathways
12.41 CREB1 MAPK3 MTOR SP1
38
Show member pathways
12.39 CXCL8 HLA-A HLA-B HLA-E HLA-G IL1B
39 12.38 FAS MAPK3 MTOR TNF
40
Show member pathways
12.38 CXCL8 IL1B IL6 MAPK3 SP1 TNF
41 12.37 CREB1 IL1B IL6 MAPK3 TNF
42
Show member pathways
12.35 CXCL8 IL6 IRF3 TNF
43
Show member pathways
12.34 CCL2 CREB1 MAPK3 MTOR
44
Show member pathways
12.34 CCL2 CCL3 CCL5 CXCL8 IL1B MAPK3
45 12.34 CREB1 CXCL8 IL1B IL6 SP1 TNF
46
Show member pathways
12.33 CXCL8 FAS IL1B IL6 TNF
47
Show member pathways
12.31 IL1B IL6 MAPK3 TNF
48 12.24 HLA-A HLA-B HLA-E HLA-G
49 12.24 CXCL8 HLA-A HLA-B HLA-E HLA-G IL6
50 12.23 B2M HLA-A HLA-B HLA-E HLA-G

GO Terms for Cytomegalovirus Infection

Cellular components related to Cytomegalovirus Infection according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.93 B2M FAS HLA-A HLA-B HLA-E TNF
2 Golgi membrane GO:0000139 9.91 B2M HLA-A HLA-B HLA-E HLA-G MTOR
3 early endosome membrane GO:0031901 9.77 B2M HLA-A HLA-B HLA-E HLA-G
4 recycling endosome membrane GO:0055038 9.65 B2M HLA-A HLA-B HLA-E HLA-G
5 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.62 HLA-A HLA-B HLA-E HLA-G
6 phagocytic vesicle membrane GO:0030670 9.55 B2M HLA-A HLA-B HLA-E HLA-G
7 ER to Golgi transport vesicle membrane GO:0012507 9.35 B2M HLA-A HLA-B HLA-E HLA-G
8 MHC class I protein complex GO:0042612 9.02 B2M HLA-A HLA-B HLA-E HLA-G
9 extracellular region GO:0005576 10.1 B2M CCL2 CCL3 CCL5 CXCL8 FAS
10 extracellular space GO:0005615 10.08 B2M CCL2 CCL3 CCL5 CXCL8 IL1B

Biological processes related to Cytomegalovirus Infection according to GeneCards Suite gene sharing:

(show top 50) (show all 70)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of DNA-binding transcription factor activity GO:0051091 9.97 IL1B IL6 TMEM173 TNF
2 neutrophil chemotaxis GO:0030593 9.95 CCL2 CCL3 CCL5 CXCL8 IL1B
3 cellular response to interleukin-1 GO:0071347 9.94 CCL2 CCL3 CCL5 CXCL8
4 chemokine-mediated signaling pathway GO:0070098 9.94 CCL2 CCL3 CCL5 CXCL8
5 cell chemotaxis GO:0060326 9.92 CCL2 CCL3 CCL5
6 positive regulation of smooth muscle cell proliferation GO:0048661 9.92 CCL5 IL6 MTOR TNF
7 type I interferon signaling pathway GO:0060337 9.92 HLA-A HLA-B HLA-E HLA-G IRF3
8 cellular response to mechanical stimulus GO:0071260 9.91 FAS IL1B MAPK3
9 positive regulation of translation GO:0045727 9.91 IL6 MAPK3 MTOR
10 monocyte chemotaxis GO:0002548 9.91 CCL2 CCL3 CCL5 IL6
11 regulation of insulin secretion GO:0050796 9.9 CCL5 IL1B TNF
12 positive regulation of T cell proliferation GO:0042102 9.89 CCL5 IL1B IL6
13 positive regulation of interleukin-6 production GO:0032755 9.89 IL1B IL6 TNF
14 humoral immune response GO:0006959 9.89 CCL2 IL6 TNF
15 visual learning GO:0008542 9.88 CREB1 MTOR RAG1
16 protein kinase B signaling GO:0043491 9.88 CCL2 CCL3 CCL5 IL1B TNF
17 cellular response to organic cyclic compound GO:0071407 9.88 CCL2 CCL3 CCL5 IL1B TMEM173 TNF
18 cellular response to amino acid starvation GO:0034198 9.87 FAS MAPK3 MTOR
19 antigen processing and presentation GO:0019882 9.87 HLA-A HLA-B HLA-E
20 positive regulation of nitric oxide biosynthetic process GO:0045429 9.86 IL1B MTOR TNF
21 lymphocyte chemotaxis GO:0048247 9.85 CCL2 CCL3 CCL5
22 cellular response to fibroblast growth factor stimulus GO:0044344 9.85 CCL2 CCL5 CXCL8
23 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.85 B2M HLA-A HLA-B HLA-E HLA-G
24 interferon-gamma-mediated signaling pathway GO:0060333 9.85 B2M HLA-A HLA-B HLA-E HLA-G IRF3
25 negative regulation of neurogenesis GO:0050768 9.83 IL1B IL6 TNF
26 eosinophil chemotaxis GO:0048245 9.83 CCL2 CCL3 CCL5
27 macrophage chemotaxis GO:0048246 9.8 CCL2 CCL3 CCL5
28 positive regulation of glial cell proliferation GO:0060252 9.8 IL1B IL6 MTOR TNF
29 positive regulation of neuroinflammatory response GO:0150078 9.75 IL1B IL6 TNF
30 negative regulation by host of viral transcription GO:0043922 9.74 CCL3 CCL5
31 PERK-mediated unfolded protein response GO:0036499 9.74 CCL2 CXCL8
32 positive regulation of immunoglobulin secretion GO:0051024 9.74 HLA-E IL6
33 regulation of type I interferon production GO:0032479 9.74 IRF3 TMEM173
34 response to molecule of bacterial origin GO:0002237 9.74 B2M CXCL8
35 neutrophil activation GO:0042119 9.73 CCL5 CXCL8
36 negative regulation of lipid storage GO:0010888 9.73 IL6 TNF
37 negative regulation of T cell apoptotic process GO:0070233 9.73 CCL5 RAG1
38 regulation of stress-activated MAPK cascade GO:0032872 9.73 FAS MAPK3
39 protection from natural killer cell mediated cytotoxicity GO:0042270 9.73 HLA-A HLA-B HLA-E
40 antigen processing and presentation of endogenous peptide antigen via MHC class Ib GO:0002476 9.73 HLA-A HLA-B HLA-E HLA-G
41 response to glucocorticoid GO:0051384 9.72 IL6 TNF
42 positive regulation of chemokine biosynthetic process GO:0045080 9.72 IL1B TNF
43 positive regulation of histone phosphorylation GO:0033129 9.72 IL1B MAPK3
44 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent GO:0002479 9.72 B2M HLA-A HLA-B HLA-E HLA-G
45 regulation of establishment of endothelial barrier GO:1903140 9.71 IL1B TNF
46 astrocyte cell migration GO:0043615 9.71 CCL2 CCL3
47 necroptotic signaling pathway GO:0097527 9.71 FAS TNF
48 positive regulation of natural killer cell chemotaxis GO:2000503 9.7 CCL3 CCL5
49 positive regulation of fever generation GO:0031622 9.7 IL1B TNF
50 sequestering of triglyceride GO:0030730 9.68 IL1B TNF

Molecular functions related to Cytomegalovirus Infection according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.85 CCL2 HLA-A HLA-B HLA-E HLA-G
2 transcription regulatory region DNA binding GO:0044212 9.81 CREB1 IRF3 SP1 TNF
3 chemokine activity GO:0008009 9.62 CCL2 CCL3 CCL5 CXCL8
4 peptide antigen binding GO:0042605 9.56 HLA-A HLA-B HLA-E HLA-G
5 CCR chemokine receptor binding GO:0048020 9.54 CCL2 CCL3 CCL5
6 cytokine activity GO:0005125 9.5 CCL2 CCL3 CCL5 CXCL8 IL1B IL6
7 beta-2-microglobulin binding GO:0030881 9.49 HLA-A HLA-E
8 CCR5 chemokine receptor binding GO:0031730 9.48 CCL3 CCL5
9 phospholipase activator activity GO:0016004 9.43 CCL3 CCL5
10 CCR1 chemokine receptor binding GO:0031726 9.4 CCL3 CCL5
11 identical protein binding GO:0042802 9.4 B2M CCL3 CCL5 CREB1 FAS HLA-G
12 protein binding GO:0005515 10.16 B2M CCL2 CCL3 CCL5 CREB1 CXCL8
13 protein homodimerization activity GO:0042803 10 CCL5 HLA-G IRF3 RAG1 SP1 TMEM173

Sources for Cytomegalovirus Infection

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....